Search

everythinglearnresearchcommunity

for

Search:↓

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.

Immunoadsorption successfully treated a man's resistant polymyositis.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Ruxolitinib helped a man regrow his beard after years of hair loss.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.

The combination therapy significantly improved Riehl’s melanosis in patients without serious side effects.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.